Rating Change
Chardan Capital analysts reiterated a Buy rating on iBio, Inc. (NASDAQ:IBIO) on July 02, 2026.
reiterateNASDAQ:IBIO
Chardan Capital Reiterates Buy Rating on iBio, Inc. (IBIO)
Rating Change Chardan Capital analysts reiterated a Buy rating on iBio, Inc. (NASDAQ:IBIO) on July 02, 2026. Market Context iBio, Inc.
Market Context
iBio, Inc. operates in the Healthcare sector. The stock currently trades at $1.69 with a market capitalization of $39.7M. The stock has gained 129.3% over the past 52 weeks.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for iBio, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for iBio, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 02, 2026 | Chardan Capital | Buy | N/A |
| Jun 08, 2026 | Raymond James | Outperform | N/A |
| Apr 09, 2026 | Chardan Capital | Buy | N/A |
| Mar 18, 2026 | Chardan Capital | Buy | N/A |
| Mar 03, 2026 | Jones Trading | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View IBIO Stock Page
Frequently Asked Questions
What does a Buy rating mean for IBIO?
A Buy rating from Chardan Capital reflects the analyst's outlook on iBio, Inc. (NASDAQ:IBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IBIO forecast page.